ClinicalTrials.gg
Status unknownNCT03393065LUNG US ICUUpdated Feb 26, 2019

Lung Ultrasound Guided Protocol for Fluid Management for the Critically Ill Patient: a Randomized Study

An interventional study of Fluid management guided by BLS in Critical Illness, sponsored by Professor Adrian Covic. Status unknown at 1 site in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by Professor Adrian Covic · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In the Intensive Care Unit (ICU) this bedside method of assessing lung congestion could be useful in a better management of the critically ill patients with a wide range of respiratory failure causes (Acute Respiratory Distress Syndrome, COPD, acute pulmonary edema, pneumonia etc.). Fluid management is a key issue in the ICU where patients are either hemodynamic unstable and/or mechanically ventilated. A randomized study is proposed where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.

Read the detailed description

Inclusion criteria

  • Age 18 or older admitted to the Intensive Care Unit

Exclusion criteria

  • Due to LUS measurement limitation: patients with known persistent pleurisy, pulmonary fibrosis or pneumectomy;
  • Unwillingness to participate in the study.

Active arm diuretic administration algorithm

  • Intravenous diuretics will be used only to decrease the BLS to \< 15;
  • A stepped diuretic administration algorithm is provided below;
  • Investigators may opt-out of the stepped diuretic administration algorithm if they feel it is in the best interests of the patient care;
  • Intravenous diuretics can be decreased or temporarily discontinued if there is a decrease in blood pressure or an increase in creatinine that is felt to be due to a transient episode of intravascular volume depletion. After the patient has stabilized, if BLS ≥ 15, intravenous diuretics should be reinitiated until the patient's BLS is \<15.

Active arm Initial BLS ≥ 15 Diuretic dose Previous Dose Suggested dose Furosemide (/day) Furosemide (/day) Hydrochlorothiazide (/day)

  1. ≤ 80 mg 40 mg iv bolus + 5 mg/h 0
  2. 81-160 mg 80 mg iv bolus + 10 mg/h 12.5 mg
  3. 161-240 mg 80 mg iv bolus + 20 mg/h 25 mg
  4. >240 mg 80 mg iv bolus + 30 mg/h 25 mg

At 24 hours Persistent BLS ≥ 15 Negative fluid balance > 1000 ml - reduce current diuretic regimen if desired Negative fluid balance \< 1000 ml - maintain current diuretic regimen Positive fluid balance - advance to next step in table

Dialysis initiation AKI will be diagnosed based on changes in the serum creatinine, urine output, or both (according to the KDIGO recommendations). Creatinine measurements will be performed twice per day. Every patient will have a urinary catheter and urine output will be measured every hour.

Criteria for renal replacement therapy initiation:

Stage 3 AKI (urine output \<0.3 mL/kg/h for ≥24 h and/or >3 fold increase in serum creatinine level compared with baseline or serum creatinine of ≥4 mg/dL with an acute increase of at least 0.5 mg/dL within 48 hours or

If any of the following absolute indications for RRT were present:

  • Blood urea nitrogen level higher than 112 mg/dL;
  • Serum potassium level higher than 6 mEq/L and/or with electrocardiography abnormalities;
  • Urine production lower than 200 mL per 12 hours or anuria (according to the KDIGO recommendations);
  • Organ edema in the presence of AKI resistant to diuretic treatment;
  • A pH below 7.15 in the context of either pure metabolic acidosis (Paco2 below 35 mm Hg) or mixed acidosis (Paco2 of 50 mm Hg or more without the possibility of increasing alveolar ventilation)
  • Acute pulmonary edema due to fluid overload responsible for severe hypoxemia requiring an oxygen flow rate greater than 5 liters per minute to maintain a Spo2 greater than 95% or requiring a Fio2 greater than 50% in patients receiving mechanical ventilation and despite diuretic therapy.
02

Conditions studied

  • Critical Illness

Browse trials for

Keywords

  • lung ultrasounds
  • fluid managements
  • critical care patients
03

In context

Critical Illness

1,780 studies on the registry are indexed under Critical Illness; 442 are open to participants now.

This study's planned enrollment of 10 is below the median of 90 across 926 interventional studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Professor Adrian Covic is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older admitted to the Intensive Care Unit

Exclusion criteria

Exclusion Criteria:

  • known persistent pleurisy, pulmonary fibrosis or pneumectomy (due to lung ultrasonography limitations);
  • unwillingness to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    intervention group pulmonary congestion

    in the intervention group pulmonary congestion, as assessed by the BLS will guide the diuretic and fluid management, with a target of below 15 BLS. Furthermore, in the active arm, in the patients who will require a renal replacement therapy (RRT), BLS will be used to further guide the dialysis fluid prescription.

    Other: Fluid management guided by BLS

  • No intervention
    Control group

    control group the fluid management will not be LUS guided

Interventions

  • OtherFluid management guided by BLS

    We propose a randomized study where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.

06

What researchers measure

Primary outcomes

  1. 28 days survival

    all-cause mortality

    Time frame: 28 days

Secondary outcomes

  1. Intensive care unit hospitalization

    hospitalization in ICU

    Time frame: 28 days

  2. Duration of hospitalization

    hospitalization

    Time frame: 28 days

  3. Days on mechanical ventilation

    Need for mechanical ventilatory support

    Time frame: 28 days

07

Study locations

1 of 1 sites recruiting
  • Regional Institute of Oncology, Iasi
    Iași, Romania
    Recruiting
08

References and documents

Publications

  • Ciumanghel A, Siriopol I, Blaj M, Siriopol D, Gavrilovici C, Covic A. B-lines score on lung ultrasound as a direct measure of respiratory dysfunction in ICU patients with acute kidney injury. Int Urol Nephrol. 2018 Jan;50(1):113-119. doi: 10.1007/s11255-017-1730-8. Epub 2017 Oct 30. PubMed 29086342 ↗
  • Rusu DM, Siriopol I, Grigoras I, Blaj M, Ciumanghel AI, Siriopol D, Nistor I, Onofriescu M, Sandu G, Cobzaru B, Scripcariu DV, Diaconu O, Covic AC. Lung Ultrasound Guided Fluid Management Protocol for the Critically Ill Patient: study protocol for a multi-centre randomized controlled trial. Trials. 2019 Apr 25;20(1):236. doi: 10.1186/s13063-019-3345-0. PubMed 31023358 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2017 (actual). Primary completion is estimated for Oct 2019, 22 months after the start.

Of 400 non-industry interventional studies with no phase under Critical Illness, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 22 months is close to that.

Counting every sponsor, half of 404 studies reached it within 21 months; a quarter within 12 and three quarters within 40.

Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2017
First posted
Jan 8, 2018
StartActual
Dec 1, 2017
Primary completionEst.
Oct 1, 2019
CompletionEst.
Dec 31, 2019
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03393065
Lead sponsor
Professor Adrian Covic
Responsible party
Professor Adrian Covic (Clinical Professor, Grigore T. Popa University of Medicine and Pharmacy) — Sponsor-investigator
First posted
Jan 8, 2018
Start date
Dec 1, 2017
Primary completion
Oct 1, 2019 (estimated)
Completion
Dec 31, 2019 (estimated)
Last update
Feb 26, 2019

Study contacts

covic adrian, prof
Contact
accovic@gmail.com
+40.232.301.600 ext. 1603
mihai onofriescu, prof
Contact
onomihai@yahoo.com
+40.232.301.600 ext. 1603

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion